Team
Management Team
Yann Chong TAN, PhD
Founding CEO
Co-founded multiple biotech companies which collectively raised more than $400M in funding with successful IPO exit, in which he held various C-suite roles including that of Chief Scientific Officer.
Robert PIPERNO
Senior Vice President,
Tech Ops
Extensive CMC, Manufacturing, and Quality experience in the pharmaceutical and biopharmaceutical industries for clinical and commercial gene therapies.
Christian BECK, PhD
Vice President,
Corporate Development
Unique experience in M&A, strategy and business development gained at top investment banks.
John LEE, MD, PhD
Chief Medical Officer
Board-certified cardiologist with extensive clinical development expertise in both pharma and biotech companies and led clinical development programs of a public biotech from Phase I-III.
Cheryl LEE
Vice President,
Operations
Experienced life science operator and finance leader with more than 15 years of operational experience.
Susan MALONEY
Vice President, Head of Clinical Operations
Experienced clinical research and clinical operations leader. More than 30 years of experience in a variety of complex areas, including rare and orphan indications.
Board of Directors
Andreas WALLNOEFER, PhD, MBA
Board Chairman
Over 25 years of experience in the biopharma industry including 12 years as a member of the F. Hoffmann-La Roche Pharma R&D Executive Leadership team. Involved in the development of several important medicines that reached the market at Roche and contributed to the build-up of several companies and successful M&A exits.
KHOO Shih, PhD
Board Member
ClavystBio
Mia HU, PhD
Board Member
Boehringer Ingelheim Venture Fund
Elia STUPKA, PhD
Board Member
Angelini Ventures
Amanda GETT-CHAPEROT, PhD, MBA
Board Member
Kurma Partners
Advisors
Brian BURKE, PhD
Co-Founder and Advisor
Former Research Director at the Agency for Science, Technology and Research, Singapore.
Distinguished cell biologist in the area of the nuclear envelope, including lamins and the LINC complex through the innovative use of microscopic and biochemical technologies.
Colin STEWART, PhD
Co-Founder and Advisor
Former Research Director at the Agency for Science, Technology and Research, Singapore.
Pioneer in techniques underpinning mouse experimental genetics, and developer of multiple mouse models for laminopathies for elucidating mechanisms of disease.
W James NELSON, PhD
Advisor
Professor Emeritus at Stanford University.
Eminent cell biologist with seminal contributions in mechanobiology, membrane trafficking and cellular organization.
Mark KAY, MD, PhD
Co-Founder and Advisor
Head of the Division of Human Gene Therapy; and Professor of Pediatrics and Genetics at Stanford University.
World expert in the area of gene therapy technologies for the treatment of genetic and acquired diseases, including the discovery of novel adeno-associated virus (AAV) capsids.